BLOOD 2022: Zanubrutinib Shows Positive Outcomes for Patients With Waldenström Macroglobulinemia
Complete response and very good partial response higher with zanubrutinib versus ibrutinib in phase 3 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.